Protagonist Therapeutics, Inc (PTGX) shareholders
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9,834,146 | 15.20% | 13G (passive) amendment | Sep 30, 2026 |
| Wehrly, Mark C. Joint filing with Farallon Capital Management, L.L.C. (9.99%), Dapice Joshua J. (9.99%) and 13 more | 6,433,119 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Saito Edric C. Joint filing with Wehrly, Mark C. (9.99%), Short Daniel S. (9.99%) and 15 more | 6,248,013 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Patel, Rajiv A. Joint filing with Wehrly, Mark C. (9.99%), Short Daniel S. (9.99%) and 17 more | 5,956,488 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Roderick Wong Joint filing with RTW Investments, LP (8.10%) | 5,059,053 | 8.10% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Portfolio Management | 3,533,015 | 5.53% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 3,321,554 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 3,250,003 | 5.09% | 13G (passive) | Mar 31, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (5.29%), Deep Track Biotechnology Master Fund, Ltd. (5.29%) | 3,250,000 | 5.29% | 13G (passive) | Apr 3, 2025 |
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (5.10%), Wellington Group Holdings LLP (5.10%) | 3,171,423 | 5.10% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PTGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,307,837 | 15.93% | $1.26B | +528,468 | 0.02% |
| Farallon Capital Management LLC | 6,348,906 | 9.81% | $778.25M | – | 3.59% |
| Rtw Investments, LP | 5,061,175 | 7.82% | $620.40M | +2,122 | 5.30% |
| Vanguard Portfolio Management LLC | 3,629,298 | 5.61% | $444.88M | +148,087 | 0.02% |
| Wellington Management Group Llp | 3,416,781 | 5.28% | $418.83M | −182,863 | 0.07% |
| UBS Group AG | 3,399,221 | 5.25% | $416.68M | −1,778,575 | 0.05% |
| State Street Corp | 3,321,554 | 5.13% | $407.16M | +204,805 | 0.01% |
| Vanguard Capital Management LLC | 2,853,394 | 4.41% | $349.77M | +47,498 | 0.01% |
| Johnson & Johnson | 2,449,183 | 3.78% | $300.22M | – | 37.59% |
| Invesco Ltd. | 2,340,667 | 3.62% | $286.92M | +175,997 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 2,149,662 | 3.32% | $263.51M | +484,165 | 0.03% |
| Jupiter Topco LLC | 2,129,780 | 3.29% | $261.04M | New | 0.11% |
| Geode Capital Management, LLC | 1,741,209 | 2.69% | $213.48M | +71,838 | 0.01% |
| Woodline Partners LP | 1,414,173 | 2.19% | $173.35M | – | 0.54% |
| Bank Of America Corp /De/ | 1,324,498 | 2.05% | $162.36M | +29,064 | 0.01% |
| Jennison Associates LLC | 1,151,681 | 1.78% | $141.17M | +79,670 | 0.08% |
| Perceptive Advisors LLC | 981,879 | 1.52% | $120.36M | −249,000 | 1.81% |
| ADAR1 Capital Management, LLC | 960,863 | 1.48% | $117.78M | −33,256 | 5.39% |
| Morgan Stanley | 905,992 | 1.40% | $111.06M | −112,230 | 0.01% |
| Alyeska Investment Group, L.P. | 889,298 | 1.37% | $109.01M | +296,101 | 0.28% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 343 | 76M | 100.0% | 63 / 140 | 88 / 36 | 7M | 8M |
| Q1 2026 | 320 | 79M | 100.0% | 60 / 110 | 103 / 49 | 18M | 4M |
| Q4 2025 | 316 | 71M | 100.0% | 84 / 97 | 103 / 39 | 12M | 12M |
| Q3 2025 | 275 | 71M | 100.0% | 42 / 85 | 108 / 38 | 7M | 7M |
| Q2 2025 | 273 | 71M | 100.0% | 51 / 119 | 77 / 49 | 11M | 6M |
| Q1 2025 | 275 | 65M | 100.0% | 72 / 84 | 92 / 34 | 10M | 8M |
| Q4 2024 | 241 | 64M | 98.6% | 45 / 91 | 76 / 41 | 7M | 6M |
| Q3 2024 | 240 | 62M | 96.3% | 79 / 77 | 64 / 24 | 21M | 12M |
| Q2 2024 | 188 | 59M | 91.9% | 30 / 63 | 68 / 26 | 7M | 12M |
| Q1 2024 | 185 | 64M | 98.9% | 49 / 62 | 56 / 20 | 13M | 8M |
| Q4 2023 | 156 | 59M | 91.4% | 32 / 40 | 60 / 19 | 11M | 9M |
| Q3 2023 | 144 | 57M | 87.7% | 17 / 66 | 40 / 40 | 10M | 10M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
393 funds held PTGX in Q2 2026, 53% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PTGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3,641,824 | 5.63% | $446.41M | 0.40% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,044,938 | 3.16% | $250.67M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,579,849 | 2.44% | $193.66M | 0.23% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,475,422 | 2.28% | $180.86M | 0.10% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,243,618 | 1.92% | $169.93M | 0.45% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 941,367 | 1.45% | $115.39M | 1.07% | Jun 30, 2026 |
| Vanguard Explorer Fund | 881,156 | 1.36% | $120.40M | 0.54% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 849,902 | 1.31% | $104.18M | 0.22% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 828,559 | 1.28% | $101.56M | 0.85% | Jun 30, 2026 |
| Invesco Discovery Fund | 810,087 | 1.25% | $80.65M | 1.03% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 693,466 | 1.07% | $85.01M | 0.09% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 672,659 | 1.04% | $91.91M | 0.27% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 607,713 | 0.94% | $60.50M | 1.15% | May 31, 2026 |
| Invesco S&P SmallCap Momentum ETF | 569,778 | 0.88% | $77.85M | 2.57% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 568,174 | 0.88% | $69.65M | 0.45% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dinesh V. Ph D. Patel | President and CEO, Director | 522,968 | 0.81% | Sep 10, 2026 |
| Arturo Molina Md | Chief Medical Officer | 81,397 | 0.13% | Nov 17, 2026 |
| Asif Ali | Chief Financial Officer | 59,003 | 0.09% | Oct 2, 2026 |
| Suneel Gupta | Chief Development Officer | 267,433 | 0.41% | Nov 27, 2024 |
| William D. Waddill | Director | 7,825 | 0.01% | Jun 25, 2026 |
| Bryan Giraudo | Director | 12,695 | 0.02% | May 11, 2026 |
| Harold E. Selick | Director | 84,845 | 0.13% | Mar 27, 2026 |
| Lewis T. Williams | Director | 7,825 | 0.01% | Feb 18, 2026 |
| Sarah A. O'Dowd | Director | 7,825 | 0.01% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Arturo Molina Md Chief Medical Officer | Nov 16, 2026 | Sale | −2,718 | $124.65 | $338.80K | 81,397 |
| Asif Ali Chief Financial Officer | Sep 30, 2026 | Sale(10b5-1 plan) | −46,034 | $141.78 | $6.53M | 59,003 |
| Asif Ali Chief Financial Officer | Sep 30, 2026 | Sale(10b5-1 plan) | −12,595 | $141.77 | $1.79M | 105,037 |
| Asif Ali Chief Financial Officer | Sep 30, 2026 | Option exercise | +5,312 | $12.17 | $64.65K | 117,632 |
| Asif Ali Chief Financial Officer | Sep 30, 2026 | Option exercise | +15,650 | $19.19 | $300.32K | 112,320 |
| Asif Ali Chief Financial Officer | Sep 30, 2026 | Option exercise | +28,438 | $23.42 | $666.02K | 96,670 |
| Asif Ali Chief Financial Officer | Sep 30, 2026 | Option exercise | +9,229 | $38.98 | $359.75K | 68,232 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −7,278 | $144.10 | $1.05M | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 10, 2026 | Option exercise | +7,278 | $21.58 | $157.06K | 530,246 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 9, 2026 | Option exercise | +63,548 | $21.58 | $1.37M | 586,516 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −63,548 | $146.18 | $9.29M | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 8, 2026 | Option exercise | +54,174 | $21.58 | $1.17M | 577,142 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −54,174 | $145.87 | $7.90M | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 3, 2026 | Gift | −510 | – | – | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 11, 2026 | Option exercise | +34,239 | $21.58 | $738.88K | 557,717 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −34,239 | $148.52 | $5.09M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −65,761 | $149.11 | $9.81M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 10, 2026 | Option exercise | +65,761 | $21.58 | $1.42M | 589,239 |
| William D. Waddill Director | Jun 23, 2026 | Sale(10b5-1 plan) | −9,000 | $117.94 | $1.06M | 7,825 |
| William D. Waddill Director | Jun 23, 2026 | Option exercise | +9,000 | $16.54 | $148.86K | 16,825 |
| William D. Waddill Director | Jun 10, 2026 | Option exercise | +6,000 | $16.54 | $99.24K | 16,825 |
| William D. Waddill Director | Jun 10, 2026 | Sale(10b5-1 plan) | −9,000 | $107.68 | $969.12K | 7,825 |
| William D. Waddill Director | Jun 10, 2026 | Option exercise | +3,000 | $11.80 | $35.40K | 10,825 |
| William D. Waddill Director | May 29, 2026 | Option exercise | +9,000 | $11.80 | $106.20K | 16,825 |
| William D. Waddill Director | May 29, 2026 | Sale(10b5-1 plan) | −9,000 | $99.64 | $896.76K | 7,825 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Option exercise | +75,000 | $21.58 | $1.62M | 598,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −75,000 | $100.12 | $7.51M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Sale | −75,000 | $100.12 | $7.51M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Option exercise | +75,000 | $21.58 | $1.62M | 598,478 |
| Bryan Giraudo Director | May 8, 2026 | Sale | −6,000 | $100.00 | $600.00K | 0 |
| Bryan Giraudo Director | May 8, 2026 | Sale | −5,130 | $100.00 | $513.00K | 12,695 |
| Bryan Giraudo Director | May 7, 2026 | Sale | −12,000 | $100.07 | $1.20M | 6,000 |
| Bryan Giraudo Director | May 7, 2026 | Sale | −36,000 | $100.14 | $3.61M | 27,825 |
| Bryan Giraudo Director | May 7, 2026 | Option exercise | +12,000 | $6.98 | $83.76K | 43,825 |
| Bryan Giraudo Director | May 7, 2026 | Option exercise | +24,000 | $6.45 | $154.80K | 31,825 |
| Dinesh V. Ph D. Patel President and CEO, Director | Apr 23, 2026 | Gift | −1,460 | – | – | 523,478 |
| Asif Ali Chief Financial Officer | Apr 20, 2026 | Sale | −1,750 | $105.47 | $184.57K | 59,003 |
| Harold E. Selick Director | Mar 26, 2026 | Option exercise | +24,000 | $12.88 | $309.12K | 84,845 |
| Harold E. Selick Director | Mar 26, 2026 | Sale | −24,000 | $105.00 | $2.52M | 60,845 |
| Arturo Molina Md Chief Medical Officer | Mar 26, 2026 | Option exercise | +15,000 | $8.04 | $120.60K | 99,115 |
| Arturo Molina Md Chief Medical Officer | Mar 26, 2026 | Sale | −15,000 | $104.79 | $1.57M | 84,115 |
| Asif Ali Chief Financial Officer | Mar 26, 2026 | Option exercise | +19,500 | $19.19 | $374.21K | 80,253 |
| Asif Ali Chief Financial Officer | Mar 26, 2026 | Option exercise | +5,265 | $12.17 | $64.08K | 85,518 |
| Asif Ali Chief Financial Officer | Mar 26, 2026 | Sale | −24,765 | $104.24 | $2.58M | 60,753 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 25, 2026 | Option exercise | +54,641 | $8.58 | $468.82K | 579,579 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 25, 2026 | Sale | −54,641 | $101.00 | $5.52M | 524,938 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 24, 2026 | Sale | −59 | $101.00 | $5.96K | 524,938 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 24, 2026 | Option exercise | +59 | $8.58 | $506 | 524,997 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 23, 2026 | Gift | −50,000 | – | – | 524,938 |
| Lewis T. Williams Director | Feb 17, 2026 | Sale | −18,000 | $82.42 | $1.48M | 7,825 |
| Lewis T. Williams Director | Feb 17, 2026 | Option exercise | +18,000 | $10.84 | $195.12K | 25,825 |
| William D. Waddill Director | Feb 6, 2026 | Sale | −20,000 | $83.68 | $1.67M | 7,825 |
| William D. Waddill Director | Feb 6, 2026 | Option exercise | +20,000 | $8.31 | $166.20K | 27,825 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 27, 2026 | Option exercise | +4,068 | $21.58 | $87.79K | 578,573 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 27, 2026 | Sale | −4,068 | $83.19 | $338.42K | 574,505 |
| Arturo Molina Md Chief Medical Officer | Jan 27, 2026 | Option exercise | +5,000 | $8.04 | $40.20K | 89,115 |
| Arturo Molina Md Chief Medical Officer | Jan 27, 2026 | Sale | −5,000 | $82.00 | $410.00K | 84,115 |
| Asif Ali Chief Financial Officer | Jan 27, 2026 | Sale | −18,203 | $83.14 | $1.51M | 60,320 |
| Asif Ali Chief Financial Officer | Jan 27, 2026 | Sale | −28,000 | $83.13 | $2.33M | 78,523 |
| Asif Ali Chief Financial Officer | Jan 27, 2026 | Option exercise | +16,000 | $19.19 | $307.04K | 94,523 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Protagonist Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 53,618 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Asif Ali Officer | Sep 30, 2026 | 58,629 | $8.26M | Sep 30, 2026 | Exercise of Stock Options |
| Dinesh V. Ph D. Patel CEO | Aug 10, 2026 | 225,000 | $33.58M | Aug 10, 2026 | Option Exercise |
| William D. Waddill Director | Jun 23, 2026 | 9,000 | $1.04M | Jun 23, 2026 | Exercise of Stock Options |
| William D. Waddill Director | Jun 10, 2026 | 9,000 | $952.83K | Jun 10, 2026 | Exercise of Stock Options |
| William D. Waddill Director | May 29, 2026 | 9,000 | $903.69K | May 29, 2026 | Exercise of Stock Options |
| Dinesh V. Ph D. Patel CEO | May 12, 2026 | 75,000 | $7.76M | May 12, 2026 | Option Exercise |
| Bryan M & Courtney L Giraudo Rt Director | May 8, 2026 | 11,130 | $1.11M | May 8, 2026 | Compensation |
| Bryan Giraudo Director | May 7, 2026 | 36,000 | $3.60M | May 7, 2026 | Stock Option Exercise |
| Bryan M & Courtney L Giraudo Rt Director | May 7, 2026 | 12,000 | $1.20M | May 7, 2026 | Compensation |
| Asif Ali Officer | Apr 21, 2026 | 1,750 | $184.57K | Apr 20, 2026 | Restricted stock vesting under a registered plan |
| Harold E. Selick Director | Mar 26, 2026 | 24,000 | $2.52M | Mar 26, 2026 | Stock Option Exercise |
| Arturo Molina Md Officer | Mar 26, 2026 | 15,000 | $1.57M | Mar 26, 2026 | Stock Option Exercise |
| Asif Ali Officer | Mar 26, 2026 | 24,765 | $2.58M | Mar 26, 2026 | Stock Option Exercise |
| Dinesh V. Ph D. Patel CEO | Mar 24, 2026 | 54,700 | $5.39M | Mar 24, 2026 | Option Exercise |
| Lewis T. Williams Director | Feb 17, 2026 | 18,000 | $1.48M | Feb 17, 2026 | Stock Option Exercise |
See a number that looks wrong?